Status:
COMPLETED
Therapy Pathways in the Treatment of Hormone Naïve Prostate Cancer Patients With and Without Comorbidities Treated With Degarelix or Luteinizing-Hormone-Releasing-Hormone (LHRH) Agonists.
Lead Sponsor:
Ferring Pharmaceuticals
Conditions:
Advanced Prostate Cancer
Eligibility:
MALE
Brief Summary
The purpose of this study is to detect factors influencing decision making for treatment pathways of hormone-naïve prostate cancer patients with and without comorbidities receiving medicinal androgen ...
Eligibility Criteria
Inclusion
- Diagnosed with Prostate Cancer and indicated for ADT according to Summary of Product Characteristics (SmPC)
- Decision made to prescribe ADT (Degarelix or LHRH agonist) prior to enrolment
Exclusion
- Patient had previous or is currently under hormonal management of Prostate Cancer, except for a curative intention, where the duration of the neoadjuvant/adjuvant therapy did not exceed 6 months and treatment should have been terminated at least 6 months prior to baseline.
- Participation in a clinical trial at baseline and during the follow-up period
Key Trial Info
Start Date :
September 1 2014
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
June 30 2019
Estimated Enrollment :
461 Patients enrolled
Trial Details
Trial ID
NCT02234089
Start Date
September 1 2014
End Date
June 30 2019
Last Update
July 5 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Investigational site (there may be other sites in this country)
Rottweil, Germany